|  | BV/TV (%) | TuV/TV (%) | Tb.Th. (μm) | Tb.N. (mm-1) | Tb.Sp. (μm) | Ob.Pm./B.Pm. (%) | N.Oc./BS (#/mm) |
|---|
Control | 5.88 ± 0.99 | 80.48 ± 2.49 | 31.58 ± 4.83 | 2.03 ± 0.42 | 597.24 ± 215.70 | 5.23 ± 1.03 | 4.06 ± 0.37 |
Prevention | 6.65 ± 2.31 | 78.69 ± 2.06 | 34.27 ± 2.05 | 1.84 ± 0.50 | 690.77 ± 188.80 | 9.51 ± 1.76a
| 4.37 ± 0.71 |
Treatment | 6.75 ± 1.72 | 77.85 ± 2.99 | 36.00 ± 4.80 | 1.79 ± 0.37 | 633.46 ± 193.00 | 8.35 ± 2.66 | 6.32 ± 0.50b
|
- Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical significance was evaluated using student's paired t test. a Control vs. prevention (p < 0.05). b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface.
